Sunset of Tower Bridge and the London skyline over the River Thames, the surroundings of the corporate representation of the Ferrer group in the United Kingdom.

Global presence

Ferrer UK

Worker smiling at a meeting of the Ferrer Group.

At Ferrer, improving the lives of people living with serious and complex illnesses is at the heart of our purpose. This guides the way we innovate, collaborate and operate across all of our subsidiaries. Ferrer UK has been established to develop our activities within the UK healthcare system.

 

The creation of our structure in the UK also represents an important step in reinforcing our commitment to use business to generate value, not only through our pharmaceutical activity, but also through responsible and sustainable practices. This defines how we listen to patients' needs, work with healthcare professionals, and engage with the wider community.

 

Our UK subsidiary is part of a wider effort to build a more connected and agile organisation across Europe, engage with our stakeholders and advance our purpose of using the company as a driver to fight for social justice.

Pulmonary vascular and interstitial diseases

These are serious and debilitating diseases, of low prevalence, which require a multidisciplinary clinical approach. Pulmonary vascular diseases affect the blood vessels in the lungs. Interstitial lung diseases are a group of pathologies characterized by inflammation and fibrosis of the lung parenchyma, especially the connective tissue and alveolar walls.